About This Presentation



Read here the market research report on the “Allergic Asthma Therapeutics Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:54
Updated: 3 November 2020
Slides: 20
Provided by: kunalbhuta
Category: Other


Transcript and Presenter's Notes


  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Allergic Asthma Therapeutics Market, by Drug Type
    (Corticosteroids, Bronchodilators, Leukotriene
    modifiers, Immunotherapy, Biologics, and Others),
    by Route of Administration (Oral, Inhaled, and
    Others), and by Region (North America, Latin
    America, Europe, Asia Pacific, Middle East, and
    Africa) - Size, Share, Outlook, and Opportunity
    Analysis, 2020 - 2027

  • There are lucrative opportunities for market
    players to enter potential markets in developed
    economies such as the U.S. and European
    countries, where the prevalence of chronic
    pulmonary diseases (COPD) is high.
  • According to an analysis of the ISAAC
    (International Study for Asthma and Allergy in
    Childhood) in 2018, it is indicated that the
    prevalence of allergic asthma among adolescents
    and children is higher in developed countries.
    Among underprivileged communities of these
    countries, the rate of uncontrolled asthma is
    higher. On the other hand, according to secondary
    analysis of data generated by the World Health
    Organization (WHO) in 2018, symptoms of allergic
    asthma are less frequent in middle-income
    countries compared to high and low income

  • The growing prevalence of respiratory diseases is
    expected to boost the growth of the global
    allergic asthma therapeutics market during the
    forecast period. For instance, according to the
    WHO, in 2018, around 235 million people were
    suffering from asthma and more than 200 million
    were suffering from chronic obstructive pulmonary
    disease (COPD).

Global Allergic Asthma Therapeutics Market -
Impact of Coronavirus (Covid-19) Pandemic
  • The allergic asthma therapeutics market growth is
    hugely impacted by the sudden outbreak of
    COVID-19 all across the globe. Though the risk of
    asthma patients to be affected by COVID-19 is
    higher, authorities are taking utmost precaution
    to make the critical solutions (ventilators,
    inhalers) available to the patients. Supply for
    respiratory medications have not been affected
    due this pandemic.

  • The comprehensive version of the report will
    include COVID-19s impact and the projected
    changes in the future outlook of the industry, by
    taking into the account the social, economic,
    political, and technological parameters.
  • The allergic asthma therapeutics market is
    estimated to be valued at US 6,704.8
    million in 2020 and is expected to exhibit a CAGR
    of 2.9 during the forecast period (2020-2027).

Figure 1. Global Allergic Asthma Therapeutics
Market Share () Analysis, By Application, 2020
  • The launch and approvals of novel drugs for
    asthma treatment are expected to boost the growth
    of the global allergic asthma therapeutics market
  • Approvals and launch of novel drugs in the mark
    et are expected to propel the market growth and
    create lucrative growth opportunities for the
    market players during the forecast period.
  • For instance, in June 2017, Teva Pharmaceuticals
    Industries Limited received U.S. FDA approval for
    its two products ArmonAirTM RespiClick and
    AirDuoTM Respiclick. These products are asthma
    inhalers for adolescent and adult patients
    suffering from asthma. ArmonAir RespiClick and
    AirDuo RespiClick are available to patients in
    the U.S. through prescription. The approved
    strength of AirDuo is 232/14 mcg, 113/14 mcg, and
    55/14 mcg, whereas, the approved strengths of
    ArmonAir is 232 mcg, 113, mcg, and 55 mcg
    directed as one inhalation twice daily.

  • Furthermore, key players in the industry are
    strategically expanding to strengthen their
    position in the global market. For instance, in
    May 2019, ASLAN Pharmaceuticals, a
    Singapore-based clinical-stage immunology and
    oncology-focused biopharma company, amended its
    license agreement with CSL Limited (CSL). ASLANs
    aim behind this agreement was to have full global
    rights to develop, manufacture, and commercialize
    ASLAN004 in all indications. ASLAN004 is a
    fully human monoclonal antibody that helps in
    triggering the symptoms of allergic asthma such
    as coughing, wheezing, exacerbations of the
    disease, and shortness of breath.
  • In October 2018, Sanofi and Regeneron
    Pharmaceuticals, Inc. announced the FDA approval
    of Dupixent (dupilumab) as an added maintenance
    therapy for patients suffering from
    moderate-to-severe asthma that are aged 12 years
    and above with an oral corticosteroid-dependent
    or eosinophilic phenotype asthma.

Global Allergic Asthma Therapeutics Market
  • However, the rising patent expiration of drugs is
    a major factor which is expected to hamper the
    growth of the allergic asthma therapeutics
    market. Also, lower awareness about novel drugs
    in rural areas of Asia Pacific and Africa are
    expected to result in slower adoption of allergic
    asthma therapeutics and hinder growth of the
    allergic asthma therapeutics market.
  • Moreover, an increase in the use of generic drugs
    in such regions is also expected to restrict the
    growth of the allergic asthma therapeutics market
    during the forecast period.

(No Transcript)
Global Allergic Asthma Therapeutics Market
Regional Analysis
  • North America accounted for majority of share in
    the global allergic asthma therapeutics market in
    2019 owing to the presence of major market
    players and approvals of novel drugs in the
    market For instance, in September 2018, Novartis
    AG received the US Food and Drug Administration
    (FDA) approval for its prefilled syringe
    formulation, Xolair (omalizumab). Xolair has been
    approved for 75 mg and 150 mg single dose for
    both chronic idiopathic urticaria (CIU) and
    allergic asthma.

  • Moreover, diagnosis of this condition is critical
    for an effective treatment regimen. For instance,
    in September 2019, Genentech and Abionic entered
    a joint agreement to develop and provide quick
    point-of-care tests for asthma in the U.S.
    Genentech is funding the clinical and regulatory
    costs, whereas, Abionic has managed the
    pre-market procedure for the specific asthma
  • Furthermore, Asia Pacific is expected to witness
    significant growth in the global allergic asthma
    therapeutics market owing to initiatives taken by
    key players. Companies such as Aslan
    Pharmaceuticals, Kineta, and others are investing
    in research and development of novel drugs for
    allergic asthma.       

  • Figure 2. Global Allergic Asthma Therapeutics
    Market Value (US Mn) Y-o-Y Growth (),

Global Allergic Asthma Therapeutics Market -
Competitive Landscape
  • Key players operating in the global allergic
    asthma therapeutics market are Aslan
    Pharmaceuticals Pte. Ltd., Baxalta Incorporated,
    Axikin Pharmaceuticals, Chiesi Farmaceutici SpA,
    CSL Limited, Circassia Pharmaceuticals Plc,
    Fountain Biopharma Inc., Hydra Biosciences,
    GlaxoSmithKline Plc, Infinity Pharmaceuticals,
    Mabtech Limited, Kineta, Marinomed Biotechnologie
    Gmb, NeoPharm Co., Mycenax Biotech Inc., Panacea
    Biotec Limited, and Oxagen Limited.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Reference https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//
Write a Comment
User Comments (0)